Advances in Cell-based therapies for peripheral arterial disease.
Ribeiro M.
Narrative Review on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, Immune Modulation, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Tissue Cell (2025)
- Country
- Scotland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40250109
- DOI
- 10.1016/j.tice.2025.102909
- Citations
- 2
Abstract (original English)
Peripheral arterial disease (PAD) affects more than 230 million individuals worldwide, with critical limb ischemia (CLI) representing its most severe and life-threatening stage. Despite advances in pharmacological management and revascularization techniques, up to 40% of patients with CLI remain unsuitable for conventional interventions, underscoring the need for alternative therapeutic strategies. Cell-based therapies have emerged as a potential regenerative approach aimed at restoring microvascular perfusion, enhancing wound healing, and preventing limb loss. This narrative review critically examines the clinical translation of cell therapies for vascular regeneration, with a focus on CLI and diabetic foot ulcers. We compare the efficacy, safety, and translational maturity of major cell sources, including autologous bone marrow- and adipose-derived mesenchymal stromal cells, umbilical cord-derived cells, fetal progenitor cells, and induced pluripotent stem cell-based platforms. Current clinical evidence suggests heterogeneous efficacy across cell types, with overall favorable safety profiles but inconsistent functional outcomes. Increasing evidence indicates that paracrine signaling, immunomodulation, and angiogenic factor secretion play a more decisive role in therapeutic benefit than direct cellular engraftment or differentiation. Major barriers to clinical adoption include
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Efficacy of Stem Cell-Derived Exosomes in Promoting Diabetic Foot Ulcer Healing: A Meta-Analysis of Preclinical Animal Studies.
Meta-analysis on Diabetic Foot, Chronic Wound, published in J Diabetes Res (2026) — summary generated from the PubMed abstract.
- 2026
J Diabetes Res - Level AMeta-analysisEurope PMC
Bone marrow-derived mesenchymal stem cells combined with intramuscular injection promote the healing of diabetic foot ulcers: a systematic review and meta-analysis
Meta-analysis with a reported sample of 2059 on Diabetic Foot, Chronic Wound, published in Front Endocrinol (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 2059
Front Endocrinol (Lausanne) - Level AMeta-analysisEurope PMC
Comparative efficacy of advanced therapeutic modalities for diabetic foot ulcers: a systematic review and meta-analysis including NPWT, stem cells, ESWT, and bioengineered treatments
Meta-analysis on Diabetic Foot, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.
- 2026
Front Bioeng Biotechnol - Level AMeta-analysisPubMed
Therapeutic potential of adipose-derived stem cells for diabetic foot ulcers: a systematic review and meta-analysis.
Meta-analysis on Diabetic Foot, Chronic Wound, published in Diabetol Metab Syndr (2025) — summary generated from the PubMed abstract.
- 2025
Diabetol Metab Syndr6 citations - Level AMeta-analysisPubMed
A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus.
Meta-analysis on Diabetic Foot, Autoimmune Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
Comparison of the efficacy of 12 interventions in the treatment of diabetic foot ulcers: a network meta-analysis
Meta-analysis with a reported sample of 356 on Diabetic Foot, Chronic Wound, published in PeerJ (2025) — summary generated from the PubMed abstract.
- 2025
- n = 356
PeerJ1 citations